Skip to main content
ILYANG PHARMACEUTICAL CO.,LTD logo

ILYANG PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 007570 ISIN · KR7007570005 KO Manufacturing
Open in API
Filings indexed 225 across all filing types
Latest filing 2021-03-11 Audit Report / Informat…
Country KR South Korea
Listing KO 007570

About ILYANG PHARMACEUTICAL CO.,LTD

https://www.ilyang.co.kr

Ilyang Pharmaceutical, established in 1946, is a research-oriented company that develops and manufactures a diverse portfolio of pharmaceutical products. The company focuses on developing new chemical entities (NCEs) and produces a range of medicines targeting digestive, respiratory, and circulatory system disorders, as well as neoplasms and infectious diseases. Key developments include 'Ilaprazole' (Noltec), a proton pump inhibitor for acid-related disorders, and 'Supect' (Radotinib), a treatment for chronic myeloid leukemia. Its product line also encompasses general drugs, antibiotics, anti-inflammatory agents, nutritional supplements, and well-established consumer health brands like the digestive aid 'NORUMO' and the nutritional drink 'Wonbi-D'.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing titled 'Audit Report Submission' (감사보고서 제출) from Il-Yang Pharmaceutical. It provides a summary of the audit opinion (unqualified/appropriate) and key financial data (assets, liabilities, revenue, net income) for both consolidated and separate financial statements. While it contains financial data, it is a short, standardized regulatory disclosure announcing the completion and submission of the audit report to the regulator, rather than the full annual report itself. Therefore, it is classified as an Audit Report / Information document. FY 2020
2021-03-11 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Il-Yang Pharmaceutical. It outlines the date, location, and agenda items (such as financial report reporting and director remuneration approval) for the upcoming meeting. This document serves as the official notification and solicitation of shareholder attendance for the meeting, which falls under the category of Proxy Solicitation & Information Statement.
2021-03-11 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Ilyang Pharmaceutical Co., Ltd. It contains the meeting agenda, date, location, and detailed information regarding board activities, remuneration, and financial statements to be presented at the upcoming Annual General Meeting (AGM). This document is a standard proxy statement/notice package provided to shareholders to inform them of the meeting and request their participation/voting. According to the provided definitions, this fits the 'Proxy Solicitation & Information Statement' (PSI) category.
2021-03-11 Korean
주주총회집중일개최사유신고
AGM Information Classification · 95% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the scheduling of a General Meeting of Shareholders on a 'concentrated date'. It explains the reasons for the scheduling conflict and references the 'Notice of Convocation of General Meeting of Shareholders' as a separate document. Since it is a regulatory notification regarding meeting logistics rather than the meeting materials themselves or the results, it falls under the general regulatory filing category.
2021-03-11 Korean
기타경영사항(자율공시)
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure (voluntary disclosure) from Il-Yang Pharmaceutical regarding the results of a Phase 3 clinical trial for the drug Radotinib in Russia. It reports that the drug failed to demonstrate superior efficacy compared to standard treatment, leading to the cancellation of marketing approval applications for COVID-19. As this is a specific regulatory announcement regarding clinical trial outcomes and business operations that does not fit into financial reporting or specific corporate action categories, it is classified as a general regulatory filing.
2021-03-04 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure from Il-Yang Pharmaceutical regarding the results of a Phase 3 clinical trial for the drug Ilaprazole. It is a formal announcement of a material event (clinical trial outcome) filed with a regulatory body. Since it does not fit into specific categories like financial reports, dividends, or board changes, and is a standard regulatory disclosure of a material event, it falls under the RNS (Regulatory Filings) category.
2021-03-03 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.